Carregant...
4CPS-107 An estimate of avoided costs for drugs in patients included in non-small lung cancer clinical trials
BACKGROUND: The economic impact of non-small cell lung cancer (NSCLC) is increasing. Clinical trials (CT) are essential for evaluating the efficacy and safety of new treatments, but they can also have an economic benefit by avoiding drug costs. PURPOSE: Our aim was to determine the avoided cost attr...
Guardat en:
| Publicat a: | Eur J Hosp Pharm |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Group
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535720/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.198 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|